---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-017625"
form_type: "8-K"
ticker: "ABEO"
cik: "0000318306"
company_name: "ABEONA THERAPEUTICS INC."
filed_at: "2024-05-03T23:59:59+00:00"
generated_at: "2026-06-02T23:24:52.663258+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Abeona reports preliminary Q1 cash $62.7M; terminates $106M ATM prospectus

## Summary
- Preliminary cash, equivalents, and investments of $62.7M as of March 31, 2024.
- Terminated June 2023 ATM prospectus covering up to $106M in common shares.
- No sales under Sales Agreement until a new prospectus or registration statement is filed.
- Sales Agreement itself remains in effect; only the specific supplement is suspended.

## SEC filing metadata
- accession: 0001493152-24-017625
- form_type: 8-K
- ticker: ABEO
- cik: 0000318306
- company_name: ABEONA THERAPEUTICS INC.
- filed_at: 2024-05-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/318306/000149315224017625/0001493152-24-017625-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/318306/000149315224017625/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-017625
- JSON: https://secwatch.observer/filing/0001493152-24-017625.json
- Plain text: https://secwatch.observer/filing/0001493152-24-017625.txt

## Key facts
- Earnings Releases
  ABEONA THERAPEUTICS INC. reported preliminary financial results for the quarter ended March 31, 2024.
  - Period: the quarter ended March 31, 2024
  - Result: preliminary results
  source text: the Company’s cash, cash equivalents, restricted cash and short-term investments were approximately $62.7 million. This financial information is preliminary and subject to change in connection with the completion of the Company’s financial statements for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/318306/000149315224017625/0001493152-24-017625-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.